On the stock market since 2020, it operates in the world of health and science. It has 3 employees. Now — the numbers.
This is an established company with proven profits.
If every debt were paid off today, $5.1M would still be left in the vault — a solid cushion for hard times.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
The price looks reasonable next to what the company earns.
Clearly below the class average.
Clearly below the class average.
Growth: Sales growth trails the sector average.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 12 months, company executives reported 19 buys and 0 sells. Management buying with its own money is usually read as a good sign.
The stock sits at $0.0040. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
The growth engine is running at low revs right now. Report-card grade: 11/100.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 16/100.
On our five-subject report card, PTPI sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: PTPI is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.